Association between MTHFR C677T polymorphism and risk of acute lymphoblastic leukemia: A meta-analysis based on 51 case-control studies

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 740-748

  Li, Su Yi ^a,b   Ye, Jie Yu ^a   Liang, En Yu ^a   Zhou, Li Xia ^a   Yang, Mo ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

10 Methylenetetrahydrofolate Reductase (FADH2); 5; Meta Analysis; Precursor Cell Lymphoblastic Leukemia Lymphoma

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN;

ARTICLE; DISEASE PREDISPOSITION; DNA POLYMORPHISM; HUMAN; LYMPHATIC LEUKEMIA; META ANALYSIS; ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; CASE CONTROL STUDY; ENZYMOLOGY; ETHNIC GROUP; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; PUBLISHING; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

AGE FACTORS; CASE-CONTROL STUDIES; ETHNIC GROUPS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PUBLICATION BIAS; RISK FACTORS;

EID: 84924729700     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.892835     Document Type: Article

References (83)

1. Inaba H, Greaves M, Mullighan CG: Acute lymphoblastic leukaemia. Lancet, 2013; 381: 1943–55.
2. Wiemels J: Perspectives on the causes of childhood leukemia. Chem Biol Interact, 2012; 196: 59–67.
3. Sherborne AL, Hosking FJ, Prasad RB et al: Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet, 2010; 42: 492–94.
4. Prasad RB, Hosking FJ, Vijayakrishnan J et al: Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. Blood, 2010; 115: 1765–67.
5. Trevino LR, Yang W, French D et al: Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet, 2009; 41: 1001–5.
6. Narayanan S, McConnell J, Little J et al: Associations between two common variants C677T and A1298C in the methylenetetrahydrofolate reductase gene and measures of folate metabolism and DNA stability (strand breaks, misincorporated uracil, and DNA methylation status) in human lymphocytes in vivo. Cancer Epidemiol Biomarkers Prev, 2004; 13: 1436–43.
7. Skibola CF, Smith MT, Kane E et al: Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA, 1999; 96: 12810–15.
8. Takahashi T, Shivapurkar N, Reddy J et al: DNA methylation profiles of lymphoid and hematopoietic malignancies. Clin Cancer Res, 2004; 10: 2928–35.
9. Agirre X, Roman-Gomez J, Vazquez I et al: Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Int J Cancer, 2006; 118: 1945–53.
10. Claus R, Plass C, Armstrong SA, Bullinger L: DNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights. Future Oncol, 2010; 6: 1415–31.
11. McGovern AP, Powell BE, Chevassut TJ: A dynamic multi-compartmental model of DNA methylation with demonstrable predictive value in hematological malignancies. J Theor Biol, 2012; 310: 14–20.
12. Roller A, Grossmann V, Bacher U et al: Landmark analysis of DNMT3A mutations in hematological malignancies. Leukemia, 2013; 27: 1573–78.
13. Solary E, Bernard OA, Tefferi A et al: The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia, 2014; 28: 485–96.
14. Goyette P, Pai A, Milos R et al: Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR). Mamm Genome, 1998; 9: 652–56.
15. Frosst P, Blom HJ, Milos R et al: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet, 1995; 10: 111–13.
16. Lievers KJ, Boers GH, Verhoef P et al: A second common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its relationship to MTHFR enzyme activity, homocysteine, and cardiovascular disease risk. J Mol Med (Berl), 2001; 79: 522–28.
17. Weisberg I, Tran P, Christensen B et al: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab, 1998; 64: 169–72.
18. Tong N, Fang Y, Li J et al: Methylenetetrahydrofolate reductase polymorphisms, serum methylenetetrahydrofolate reductase levels, and risk of childhood acute lymphoblastic leukemia in a Chinese population. Cancer Sci, 2010; 101: 782–86.
19. Damnjanovic T, Milicevic R, Novkovic T et al: Association between the methylenetetrahydrofolate reductase polymorphisms and risk of acute lymphoblastic leukemia in Serbian children. J Pediatr Hematol Oncol, 2010; 32: e148–e150.
20. Chatzidakis K, Goulas A, Athanassiadou-Piperopoulou F et al: Methylenetetrahydrofolate reductase C677T polymorphism: association with risk for childhood acute lymphoblastic leukemia and response during the initial phase of chemotherapy in greek patients. Pediatr Blood Cancer, 2006; 47: 147–51.
21. Franco RF, Simoes BP, Tone LG et al: The methylenetetrahydrofolate reductase C677T gene polymorphism decreases the risk of childhood acute lymphocytic leukaemia. Br J Haematol, 2001; 115: 616–18.
22. Nikbakht M, MalekZadeh K, Kumar Jha A et al: Polymorphisms of MTHFR and MTR genes are not related to susceptibility to childhood ALL in North India. Exp Oncol, 2012; 34: 43–48.
23. Azhar MR, Rahimi Z, Vaisi-Raygani A et al: Lack of association between MTHFR C677T and A1298C polymorphisms and risk of childhood acute lymphoblastic leukemia in the Kurdish population from Western Iran. Genet Test Mol Biomarkers, 2012; 16: 198–202.
24. Karathanasis NV, Stiakaki E, Goulielmos GN, Kalmanti M: The role of the methylenetetrahydrofolate reductase 677 and 1298 polymorphisms in Cretan children with acute lymphoblastic leukemia. Genet Test Mol Biomarkers, 2011; 15: 5–10.
25. Sadananda Adiga MN, Chandy S, Ramachandra N et al: Methylenetetrahydrofolate reductase gene polymorphisms and risk of acute lymphoblastic leukemia in children. Indian J Cancer, 2010; 47: 40–45.
26. Lightfoot TJ, Johnston WT, Painter D et al: Genetic variation in the folate metabolic pathway and risk of childhood leukemia. Blood, 2010; 115: 3923–29.
27. Silva RM, Fontes AC, Silva KA et al: Polymorphisms involved in folate metabolism pathways and the risk of the development of childhood acute leukemia. Genet Test Mol Biomarkers, 2013; 17: 147–52.
28. Zintzaras E, Doxani C, Rodopoulou P et al: Variants of the MTHFR gene and susceptibility to acute lymphoblastic leukemia in children: a synthesis of genetic association studies. Cancer Epidemiol, 2012; 36: 169–76.
29. Yan J, Yin M, Dreyer ZE et al: A meta-analysis of MTHFR C677T and A1298C polymorphisms and risk of acute lymphoblastic leukemia in children. Pediatr Blood Cancer, 2012; 58: 513–18.
30. Wang H, Wang J, Zhao L et al: Methylenetetrahydrofolate reductase polymorphisms and risk of acute lymphoblastic leukemia-evidence from an updated meta-analysis including 35 studies. BMC Med Genet, 2012; 13: 77.
31. Wang H, Meng L, Zhao L et al: Methylenetetrahydrofolate reductase polymorphism C677T is a protective factor for pediatric acute lymphoblastic leukemia in the Chinese population: a meta-analysis. Genet Test Mol Biomarkers, 2012; 16: 1401–7.
32. Tong N, Sheng X, Wang M et al: Methylenetetrahydrofolate reductase gene polymorphisms and acute lymphoblastic leukemia risk: a meta-analysis based on 28 case-control studies. Leuk Lymphoma, 2011; 52: 1949–60.
33. Wang J, Zhan P, Chen B et al: MTHFR C677T polymorphisms and childhood acute lymphoblastic leukemia: a meta-analysis. Leuk Res, 2010; 34: 1596–600.
34. Koppen IJ, Hermans FJ, Kaspers GJ: Folate related gene polymorphisms and susceptibility to develop childhood acute lymphoblastic leukaemia. Br J Haematol, 2010; 148: 3–14.
35. Zintzaras E, Koufakis T, Ziakas PD et al: A meta-analysis of genotypes and haplotypes of methylenetetrahydrofolate reductase gene polymorphisms in acute lymphoblastic leukemia. Eur J Epidemiol, 2006; 21: 501–10.
36. Pereira TV, Rudnicki M, Pereira AC et al: 5,10-Methylenetetrahydrofolate reductase polymorphisms and acute lymphoblastic leukemia risk: a metaanalysis. Cancer Epidemiol Biomarkers Prev, 2006; 15: 1956–63.
37. Zheng MM, Yue LJ, Zhang HH et al: Association of single nucleotide polymorphism of methylenetetrahydrofolate reductase gene with susceptibility to acute leukemia. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2013; 30: 451–55.
38. Hussain SR, Naqvi H, Raza ST et al: Methylenetetrahydrofolate reductase C677T genetic polymorphisms and risk of leukaemia among the North Indian population. Cancer Epidemiol, 2012; 36: e227–e231.
39. Feng YC, Wu JR: Relationship between genetic polymorphism of methylenetetrahydrfolate reductase and the risk of childhood acute lymphocytic leukemia. Journal of Leukemia & Lymphoma, 2012; 21: 736–38.
40. Zintzaras E, Lau J: Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol, 2008; 61: 634–45.
41. Liberati A, Altman DG, Tetzlaff J et al: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol, 2009; 62: e1–e34.
42. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ, 2003; 327: 557–60.
43. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997; 315: 629–34.
44. Amigou A, Rudant J, Orsi L et al: Folic acid supplementation, MTHFR and MTRR polymorphisms, and the risk of childhood leukemia: the ESCALE study (SFCE). Cancer Causes Control, 2012; 23: 1265–77.
45. Yang L, Liu L, Wang J et al: Polymorphisms in folate-related genes: impact on risk of adult acute lymphoblastic leukemia rather than pediatric in Han Chinese. Leuk Lymphoma, 2011; 52: 1770–76.
46. te Winkel ML, de Muinck Keizer-Schrama SM, de Jonge R et al: Germline variation in the MTHFR and MTRR genes determines the nadir of bone density in pediatric acute lymphoblastic leukemia: a prospective study. Bone, 2011; 48: 571–77.
47. Chan JY, Ugrasena DG, Lum DW et al: Xenobiotic and folate pathway gene polymorphisms and risk of childhood acute lymphoblastic leukaemia in Javanese children. Hematol Oncol, 2011; 29: 116–23.
48. Yeoh AE, Lu Y, Chan JY et al: Genetic susceptibility to childhood acute lymphoblastic leukemia shows protection in Malay boys: results from the Malaysia-Singapore ALL Study Group. Leuk Res, 2010; 34: 276–83.
49. Sood S, Das R, Trehan A et al: Methylenetetrahydrofolate reductase gene polymorphisms: association with risk for pediatric acute lymphoblastic leukemia in north Indians. Leuk Lymphoma, 2010; 51: 928–32.
50. Lv L, Wu C, Sun H et al: Combined 677CC/1298AC genotypes of methylenetetrahydrofolate reductase (MTHFR) reduce susceptibility to precursor B lymphoblastic leukemia in a Chinese population. Eur J Haematol, 2010; 84: 506–12.
51. Pietrzyk JJ, Madetko-Talowska A, Bik-Multanowski M, Oltarzewski M: Additional risk factor for the development of ALL. Pediatr Blood Cancer, 2009; 53: 515.
52. Kim HN, Kim YK, Lee IK et al: Association between polymorphisms of folatemetabolizing enzymes and hematological malignancies. Leuk Res, 2009; 33: 82–87.
53. de Jonge R, Tissing WJ, Hooijberg JH et al: Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. Blood, 2009; 113: 2284–89.
54. Giovannetti E, Ugrasena DG, Supriyadi E et al: Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia. Leuk Res, 2008; 32: 19–24.
55. Alcasabas P, Ravindranath Y, Goyette G et al: 5,10-methylenetetrahydrofolate reductase (MTHFR) polymorphisms and the risk of acute lymphoblastic leukemia (ALL) in Filipino children. Pediatr Blood Cancer, 2008; 51: 178–82.
56. Petra BG, Janez J, Vita D: Gene-gene interactions in the folate metabolic pathway influence the risk for acute lymphoblastic leukemia in children. Leuk Lymphoma, 2007; 48: 786–92.
57. Oh D, Kim NK, Jang MJ et al: Association of the 5,10-methylenetetrahydrofolate reductase (MTHFR C677T and A1298C) polymorphisms in Korean patients with adult acute lymphoblastic leukemia. Anticancer Res, 2007; 27: 3419–24.
58. Kamel AM, Moussa HS, Ebid GT et al: Synergistic effect of methyltetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphism as risk modifiers of pediatric acute lymphoblastic leukemia. J Egypt Natl Canc Inst, 2007; 19: 96–105.
59. Bolufer P, Collado M, Barragan E et al: The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. Haematologica, 2007; 92: 308–14.
60. Zanrosso CW, Hatagima A, Emerenciano M et al: The role of methylenetetrahydrofolate reductase in acute lymphoblastic leukemia in a Brazilian mixed population. Leuk Res, 2006; 30: 477–81.
61. Timuragaoglu A, Dizlek S, Uysalgil N et al: Methylenetetrahydrofolate reductase C677T polymorphism in adult patients with lymphoproliferative disorders and its effect on chemotherapy. Ann Hematol, 2006; 85: 863–68.
62. Reddy H, Jamil K: Polymorphisms in the MTHFR gene and their possible association with susceptibility to childhood acute lymphocytic leukemia in an Indian population. Leuk Lymphoma, 2006; 47: 1333–39.
63. Kim NK, Chong SY, Jang MJ et al: Association of the methylenetetrahydrofolate reductase polymorphism in Korean patients with childhood acute lymphoblastic leukemia. Anticancer Res, 2006; 26: 2879–81.
64. Hur M, Park JY, Cho HC et al: Methylenetetrahydrofolate reductase A1298C genotypes are associated with the risks of acute lymphoblastic leukaemia and chronic myelogenous leukaemia in the Korean population. Clin Lab Haematol, 2006; 28: 154–59.
65. Thirumaran RK, Gast A, Flohr T et al: MTHFR genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia. Blood, 2005; 106: 2590–91; author reply 2591–92.
66. Schnakenberg E, Mehles A, Cario G et al: Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population. BMC Med Genet, 2005; 6: 23.
67. Oliveira E, Alves S, Quental S et al: The MTHFR C677T and A1298C polymorphisms and susceptibility to childhood acute lymphoblastic leukemia in Portugal. J Pediatr Hematol Oncol, 2005; 27: 425–29.
68. Krajinovic M, Lamothe S, Labuda D et al: Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood, 2004; 103: 252–57.
69. Gemmati D, Ongaro A, Scapoli GL et al: Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin’s lymphoma in adults. Cancer Epidemiol Biomarkers Prev, 2004; 13: 787–94.
70. Chiusolo P, Reddiconto G, Cimino G et al: Methylenetetrahydrofolate reductase genotypes do not play a role in acute lymphoblastic leukemia pathogenesis in the Italian population. Haematologica, 2004; 89: 139–44.
71. Deligezer U, Akisik E, Dalay N: Genotyping of the MTHFR gene polymorphism, C677T in patients with leukemia by melting curve analysis. Mol Diagn, 2003; 7: 181–85.
72. Balta G, Yuksek N, Ozyurek E et al: Characterization of MTHFR, GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes in childhood acute leukemia. Am J Hematol, 2003; 73: 154–60.
73. Yu J: Association of drug metabolizing enzymes genetic polymorphisms with the susceptibility and methotrexate induced toxicities in childhood acute leukemia. Guangzhou: Southern Medical University, 2010.
74. Chen BA, Jiang N, Ji MJ et al: A new method for 5,10-methylenetetrahydrofolate reductase single nucleotide polymorphisms genotyping used to study susceptibility of hematological malignancy. J Exp Hematol, 2006; 14: 1069–73.
75. Jiang H, Gu LJ, Xue HL et al: Methylenetetrahydrofolate reductase gene polymorphism in childhood acute lymphocytic leukaemia. Chinese Journal of Hematology, 2004; 25: 439–40.
76. Yang Z, He ZK: The association between MTHFR and RFC1 genetic polymorphisms and the risk of acute lymphoblastic leukemia in children. Hunan Provincial Committee of the Pharmacetical Professional Conference, 2009; 80–83.
77. Zhang J: A study on the serum folate level and methylenetetrahydrofolate reductase genetic polymorphisms in adult acute lymphocytic leukemia. Shijiazhuang: Hebei Medical University, 2007.
78. Lv H, Wang W, Du ZZ et al: Relationship between genetic polymorphism of methylenetetrahydrofolate reductase and the risk of childhood acute lymphocytic leukemia. J Clin Pediatr, 2011; 29: 414–17.
79. Liu JX, Chen JP, Lin DX: Relationship between genetic polymorphism of methylenetetrahydrofolate reductase and the risk of acute lymphocytic leukemia. Med J Chin PLA, 2008; 33: 1291–93.
80. Yu H, Jin RM, Bai Y et al: The relationship between the methylenetetrahydrofolate reductase C677T gene polymorphism and acute lymphocytic leukemia in children. Journal of Clinical Hematology, 2006; 19: 205–6.
81. Jiang Y, Hou J, Zhang Q et al: The MTHFR C677T polymorphism and risk of acute lymphoblastic leukemia: an updated meta-analysis based on 37 case-control studies. Asian Pac J Cancer Prev, 2013; 14: 6357–62.
82. Bolufer P, Barragan E, Collado M et al: Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression. Leuk Res, 2006; 30: 1471–91.
83. Xia J, Wang Y, Zhang H, Hu Y: Association between MTR A2756G polymorphism and childhood acute lymphoblastic leukemia: a meta-analysis. Leuk Lymphoma, 2013; 55: 1388–93.